Back to Browse Journals » OncoTargets and Therapy » Volume 3

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Authors Steven E McCormack, Erica D Warlick

Published 22 July 2010 Volume 2010:3 Pages 157—165


Review by Single-blind

Peer reviewer comments 4

Steven E McCormack, Erica D Warlick

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to ­significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.

Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Impact of noncommunicable diseases in the State of Qatar

Al-Kaabi SK, Atherton A

ClinicoEconomics and Outcomes Research 2015, 7:377-385

Published Date: 2 July 2015

Oxidative stress and antibacterial properties of a graphene oxide-cystamine nanohybrid

Nanda SS, An SS, Yi DK

International Journal of Nanomedicine 2015, 10:549-556

Published Date: 12 January 2015

Quantitative evaluation in combination with nonquantitative evaluation in early patellar cartilage osteoarthritis at 3.0 T

Zuo HD, Yao WW, Qu N, Yang SX, Wang JH, Cui XJ

Clinical Interventions in Aging 2014, 9:1133-1143

Published Date: 16 July 2014

Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals

Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2014, 9:1139-1152

Published Date: 3 March 2014

Family medicine’s rapid establishment and early leadership role in Qatar’s health care system

Verjee MA, Abdulmalik MA, Fetters MD

Journal of Healthcare Leadership 2013, 5:47-52

Published Date: 12 August 2013

Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity

Williams JP, Southern P, Lissina A, Christian HC, Sewell AK, Phillips R, Pankhurst Q, Frater J

International Journal of Nanomedicine 2013, 8:2543-2554

Published Date: 23 July 2013

Chronic eosinophilic pneumonia due to radiographic contrast administration: an orphan disease?

Hohenforst-Schmidt W, Riedel A, Zarogoulidis P, Franke C, Gschwendtner A, Huang H, Machairiotis N, Dramba V, Zarogoulidis K, Brachmann J

Drug Design, Development and Therapy 2012, 6:385-389

Published Date: 10 December 2012

Epidemiology of chronic obstructive pulmonary disease: a literature review

Rycroft CE, Heyes A, Lanza L, Becker K

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:457-494

Published Date: 20 July 2012

The western diet and lifestyle and diseases of civilization

Pedro Carrera-Bastos, Maelan Fontes-Villalba, James H O’Keefe, et al

Research Reports in Clinical Cardiology 2011, 2:15-35

Published Date: 9 March 2011

Update on current and emerging treatment options for post-polio syndrome

Elisabeth Farbu

Therapeutics and Clinical Risk Management 2010, 6:307-313

Published Date: 7 July 2010